Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Axillary lymph node dissection in clinically node-positive breast cancer].

Hiroji Iwata1, Shigeto Miura

  • 1Department of Breast Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

Nihon Geka Gakkai Zasshi
|December 14, 2002
PubMed
Summary

For breast cancer patients with positive lymph nodes, axillary lymph node dissection is recommended. Level I and II dissection is preferred, with Level III reserved for intraoperative findings to improve local control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events.

NPJ breast cancer·2026
Same author

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.

Breast cancer (Tokyo, Japan)·2026
Same author

Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial.

Breast cancer (Tokyo, Japan)·2026
Same author

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

NPJ breast cancer·2026
Same author

Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study.

International journal of clinical oncology·2026
Same author

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.

Breast cancer (Tokyo, Japan)·2026

Area of Science:

  • Oncology
  • Surgical Oncology
  • Evidence-Based Medicine

Context:

  • Clinically node-positive breast cancer is often considered a systemic disease by many Japanese surgeons.
  • A significant majority of surgeons believe axillary lymph node dissection improves survival rates.
  • Surgical approaches are frequently modified based on intraoperative lymph node metastasis assessment.

Purpose:

  • To analyze axillary lymph node dissection strategies for clinically node-positive breast cancer using evidence-based medicine.
  • To provide recommendations for optimal surgical management to improve patient outcomes.

Summary:

  • Evidence-based analysis suggests Level I and II axillary lymph node dissection as the preferred method for clinically node-positive breast cancer.
  • Removal of Level III axillary nodes is generally not necessary for accurate staging.

Related Experiment Videos

  • Level III dissection is recommended only when grossly positive nodes are detected during surgery to enhance local disease control.

    • Impact:

    • This study provides evidence-based recommendations to refine surgical guidelines for axillary lymph node dissection in breast cancer.
    • Implementing these recommendations may lead to more standardized and effective surgical practices, potentially improving local control and patient outcomes.